20 minute delayed
Join Market Matters and get full access to all our Opinion + Action
Undervalued
Morningstar Quantitative Rating as of 30 OCT 2026.
Quantitative Equity Rating Methodology – view here
Five-star price 6.33 Fair value 8.46 One-star price 11.31
Morningstar Quantitative Rating as of 30 OCT 2026.
Morningstar Quantitative Rating as of 30 OCT 2026. The slider runs from the five-star price (6.33) to the one-star price (11.31).
| Ratios |
|---|
| Currency (Price/reporting): AUD/AUD |
| Exchange Rate: 1.0000 |
| Price - closing or last bid | 7.22 |
| Price - 12 month high | 13.48 |
| Price - 12 month low | 6.62 |
| Pricing date | 29 OCT 2026 |
| Volume - avg. trading volume for the last ten days | 0.20 |
| Market capitalization | 364.52 |
| 12 Month High price date | 12 JAN 2026 |
| 12 Month Low price date | 20 OCT 2026 |
| Volume - avg. trading volume for the last 3 months | 0.15 |
| Price - 1 Day % Change | -1.50% |
| Price - 13 week price percent change | -24.71% |
| Price - 26 week price percent change | -22.53% |
| Price - 5 Day % Change | 2.12% |
| Price - 52 week price percent change | -36.16% |
| Price - YTD price percent change | -42.05% |
| Price % Change Month To Date | -13.84% |
| EPS excluding extraordinary items - most recent fiscal year | 0.668 |
| EPS excluding extraordinary items - trailing 12 month | 0.668 |
| EPS Normalized - most recent fiscal year | 0.669 |
| Revenue/share - most recent fiscal year | 1.852 |
| Revenue/share - trailing 12 month | 1.852 |
| Book value per share - most recent fiscal year | 5.411 |
| Book value per share - most recent half-year | 5.411 |
| Book value (tangible) per share - most recent fiscal year | 5.408 |
| Book value (tangible) per share - most recent half-year | 5.408 |
| Cash per share - most recent fiscal year | 0.424 |
| Cash per share - most recent half-year | 0.424 |
| Cash Flow per share - most recent fiscal year | 0.727 |
| Cash Flow per share - trailing 12 month | 0.727 |
| Dividend per share - most recent fiscal year | — |
| Dividends per share - trailing 12 month | 0.050 |
| EBITD per share - trailing 12 month | 0.752 |
| EPS Basic excluding extraordinary items - most recent fiscal year | 0.678 |
| EPS Basic excluding extraordinary items - trailing 12 month | 0.678 |
| EPS including extraordinary items - most recent fiscal year | 0.678 |
| EPS including extraordinary items - trailing 12 month | 0.678 |
| Free Cash Flow per share - trailing 12 month | 0.695 |
| P/E excluding extraordinary items, most recent fiscal year | 10.81 |
| P/E Normalized, most recent fiscal year | 10.80 |
| Price to sales - most recent fiscal year | 3.90 |
| Price to Tangible Book - most fiscal year | 1.34 |
| Price to Free Cash Flow per Share - most recent fiscal year | 10.38 |
| Price to Cash Flow per share - trailing 12 month | 9.93 |
| Price to Book - most recent fiscal year | 1.33 |
| P/E excluding extraordinary items high, trailing 12 months | 18.43 |
| P/E excluding extraordinary items low, trailing 12 months | 10.49 |
| Net Debt, LFI | -232.68 |
| Net Debt, LFY | -19.45 |
| Dividend Yield - 5 Year Average | 0.25% |
| Dividend Yield - indicated annual dividend divided by closing price | 0.70% |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 0.69% |
| Free Cash Flow - most recent fiscal year | 35.31 |
| LT debt/equity - most recent fiscal year | 0.57% |
| Payout ratio - most recent fiscal year | — |
| Total debt/total equity - most recent fiscal year | 0.71% |
| LT debt/equity - most recent half-year | 0.01% |
| Total debt/total equity - most recent half-year | 0.13% |
| Free Cash Flow - trailing 12 month | 35.31 |
| Payout ratio - trailing 12 month | — |
| Revenue - most recent fiscal year | 94.02 |
| Revenue - trailing 12 month | 94.02 |
| EBITD - most recent fiscal year | 38.20 |
| EBITD - trailing 12 month | 38.20 |
| Earnings before taxes - most recent fiscal year | 47.66 |
| Earnings before taxes - trailing 12 month | 47.66 |
| Net Income available to common - most recent fiscal year | 33.92 |
| Net Income available to common - trailing 12 months | 33.92 |
| Earnings before taxes Normalized - most recent fiscal year | 47.72 |
| Net Income Available to Common, Normalized - most recent fiscal year | — |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | 0.67 |
| Net Profit Margin % - 1st historical fiscal year | 36.07% |
| Net Profit Margin % - trailing 12 month | 36.07% |
| Operating margin - 1st historical fiscal year | 43.11% |
| Operating margin - trailing 12 month | 43.11% |
| Pretax margin - trailing 12 month | 50.69% |
| Pretax margin - 1st historical fiscal year | 50.69% |
| Operating Margin - 5 year average | 51.15% |
| Pretax Margin - 5 year average | 54.57% |
| Free Operating Cash Flow/Revenue, 5 Year Average | 44.40% |
| Free Operating Cash Flow/Revenue, TTM | 37.55% |
| Net Profit Margin - 5 year average | 37.08% |
| Return on average assets - most recent fiscal year | 12.16% |
| Return on average assets - trailing 12 month | 12.16% |
| Return on average equity - most recent fiscal year | 13.34% |
| Return on average equity - trailing 12 month | 13.34% |
| Return on average assets - 5 year average | 15.82% |
| Return on average equity - 5 year average | 17.92% |
| Net Income/employee - most recent fiscal year | — |
| Revenue/employee - most recent fiscal year | — |
| Revenue growth rate, 5 year | 14.40% |
| EPS growth rate, 5 year | 6.66% |
| Growth rate% - dividend, 3 year | 7.72% |
| Revenue/share (5 yr growth) | 14.55% |
| Growth rate% - Revenue, 3 year | 6.28% |
| Growth rate% - EPS, 3 year | 4.17% |
| Book value per share growth rate, 5 year | 22.05% |
| Capital Spending growth rate, 5 year | 13.40% |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | 6.52% |
Financial forecast (AUD, millions except per share)
| Actuals | Estimates | |||||||
| 2026 | 2027 | 2028 | 2029 | |||||
| Estimate breakdown | ||||||||
Financials (AUD, millions)
| Period end: | JUN 22 | JUN 23 | JUN 24 | JUN 25 | JUN 26 |
| Fiscal year: | 2022 | 2023 | 2024 | 2025 | 2026 |
| Period length: | 12 months | 12 months | 12 months | 12 months | 12 months |
Announcements
| DATE | TIME | HEADING | PAGES |
| Price sensitive |
CUV has also more than halved over the last 6-months as the high Beta biotech growth names have been throw into the naughty corner – the stories been the same in the US. This dermatology focused business is not uncommon to volatility hence at this stage we would be considering an aggressive play closer to $15 but rising competition for CUV’s Scenesse therapy would keep us cautious from a commitment perspective.
MM is neutral CUV
Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.
Forgot password? Request a One Time Password or reset your password
One Time Password
Check your email for an email from [email protected]
Subject: Your OTP for Account Access
This email will have a code you can use as your One Time Password for instant access
A link to create a new password will be sent to the email address you have registered to your account.
Hi, this is only available to members. Join today and access the latest views on the latest developments from a professional money manager.
Our Smart Phone App will give you access to much of our content and notifications. Download for free today.
Hi, this is only available to members. Join today and access the latest views on the latest developments from a professional money manager.
JOIN NOW
Something went wrong. Please try again in a moment.
